Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1310 versus investigator's choice therapy in relapsed small cell lung cancer
2025-522818-23-00Phase 3Authorised
- Sponsor
- Zai Lab
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of zocilurtatug pelitecan in small cell lung cancer (SCLC) (2 arms), sponsored by Zai Lab. Primary endpoints: Confirmed objective response rate and Overall survival. Planned start Jun 2026; status: authorised.
02
Drugs
zocilurtatug pelitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-522818-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522818-23-00.